Taurus becomes new marketing partner for Medigene's drug Veregen® in Germany
(Thomson Reuters ONE) -
Medigene AG /
Taurus becomes new marketing partner for Medigene's drug Veregen® in Germany
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Target group enlargement is expected to increase sales revenue
Martinsried/Munich, 05. December 2013. Medigene AG (MDG, Frankfurt, Prime
Standard) announces that its drug Veregen(®) for the treatment of genital warts
will be marketed by the company's new partner Taurus Pharma GmbH, Germany
beginning in January 2014. Medigene, the current partner Abbott, and the
pharmaceutical company Taurus Pharma GmbH have jointly agreed on this. The new
marketing partner will add the dermatologists, who represent an important group
of specialists to treat this skin disease, to Veregen(®) target group. The
partners anticipate that this will bring about an increase in sales of the
prescription drug. In Austria and Switzerland, Veregen(®) will continue to be
distributed by Medigene's partner Abbott in the future.
Dr. Frank Mathias, Chief Executive Officer of Medigene, comments: "The new
partnership is a gain for Veregen(® )and beneficial for the affected patients.
Thanks to many years of experience in both fields, Taurus will sell our drug not
only to gynecologists, as has been the case until now, but equally to
dermatologists. This will further expand the reach for Veregen(®)."
Klaus Seliger, Managing Director of Taurus Pharma GmbH, adds: "Veregen(®)
ideally adds to both our dermatology as well as the gynecology portfolios. Hence
Veregen(®) will play a key role in our sales activities. We look forward to
providing as many patients as possible with this innovative and reliable drug,
by extensively informing the two major physician groups treating patients that
suffer from external genital warts about the efficacious therapeutic option
Veregen(®)."
Apart from the German-speaking countries, Veregen(®) is also available in the
USA (distributed by Fougera), Spain (Bial), Serbia (Pharmanova), the Netherlands
(Will-Pharma), and Taiwan (SynCore) and has been approved in a number of
additional countries. Medigene expects the launch of Veregen(®) in other
countries within the next few months. Several marketing partnership agreements
have been concluded in Europe, Asia, and America. Medigene is planning to
continue this global licensing strategy to further tap the product's market
potential.
Veregen(®): Veregen(®), a topical treatment for external genital or perianal
warts, contains a concentrate of catechins with a complex defined composition
extracted from green tea leaves. In its current treatment guidelines for
sexually transmitted diseases, the US Center for Disease Control and Prevention
recommends Sinecatechins 15% ointment (Veregen(®)) as a possible option for
treating genital warts. In addition, Sinecatechins 10% & 15% ointments
(Veregen(®)) have been included in the current European guideline on the
treatment of genital warts, the 2012 European Guideline for the Management of
Anogenital Warts.
Taurus Pharma: Taurus Pharma GmbH, headquartered in Bad Homburg vor der Höhe,
Germany, has been selling pharmaceuticals in Germany for more than 25 years. As
a member of the Poli Group Holding, Taurus Pharma benefits from the research and
development work done by this globally operating group of companies.
Shareholders and employees are working on adding high-quality products that
provide true help for the patients in the treatment of their diseases. For this
purpose, Taurus Pharma develops and distributes an attractive range of
prescription and OTC drugs. The company's focus is on gynecology and
dermatology. For more detailed information, please visit www.tauruspharma.de.
Medigene AG (Frankfurt: MDG, prime standard) is a publicly listed biotechnology
company headquartered in Martinsried/Munich, Germany. Medigene focuses on
clinical research and development of novel drugs against cancer and autoimmune
diseases. Medigene was the first German biotech company to have revenues from
marketed products, which are distributed by partner companies. It has two drug
candidates in clinical trials, EndoTAG(®)-1 and RhuDex(®), and is developing an
innovative vaccine technology. For more information, please visit
www.medigene.com.
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®) and Veregen(®) are registered trademarks of Medigene AG. Polyphenon
E(®) is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or
licensed in select locations only.
Contact
Julia Hofmann, Claudia Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor(at)medigene.com
To unsubscribe from the press release distribution list, please go to
www.medigene.com/unsubscribe.
Press release as PDF:
http://hugin.info/132073/R/1747806/588554.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medigene AG via GlobeNewswire
[HUG#1747806]
Unternehmensinformation / Kurzprofil:
Datum: 05.12.2013 - 07:30 Uhr
Sprache: Deutsch
News-ID 322674
Anzahl Zeichen: 6427
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 165 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Taurus becomes new marketing partner for Medigene's drug Veregen® in Germany"
steht unter der journalistisch-redaktionellen Verantwortung von
Medigene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
